Anti-Alzheimer's disease marker gene, method for screening anti-Alzheimer's disease drug based on gene and drug
By using the anti-Alzheimer's marker gene pla2g12a in zebrafish models to screen anti-Alzheimer's drugs, the problem of insufficient screening efficiency and accuracy in the prior art was solved, and a more efficient drug screening process was achieved.
Patent Information
- Application Number
- CN202411002535.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2023-08-14
- Filing Date
- 2024-07-25
- Publication Date
- 2024-11-22
- Estimated Expiration
- 2044-07-25
AI Technical Summary
The existing anti-Alzheimer's drug screening methods have problems such as large data volume, long cycle and high experimental accuracy requirements in the zebrafish model, resulting in insufficient screening efficiency and accuracy.
The anti-Alzheimer's marker gene pla2g12a was used for screening. By constructing a zebrafish juvenile Alzheimer's model, combining behavioral and RT-qPCR technology, the expression trend of pla2g12a was verified to determine its anti-Alzheimer's Zheimer's disease effect.
It greatly saves drug screening time, improves screening efficiency, provides a more accurate anti-Alzheimer's drug screening method, ensuring the efficient and accurate experiments.
Smart Images

Figure FT_1 
Figure FT_2 
Figure FT_3
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of drug screening, in particular to an anti-Alzheimer's disease marker gene and a method and drug for screening anti-Alzheimer's disease drugs based on the gene, namely, application of the drug soycerebroside II in anti-Alzheimer's disease. Background Art
[0002] Alzheimer's disease (AD) is a neurodegenerative disease. Drugs that play a role in neuroprotection are likely to improve AD. People have been studying how to quickly and efficiently screen drugs against AD. Animal model drug screening is a relatively common method. This method requires the establishment of pig models, mouse models, or primate models such as monkeys. The construction of animal disease models requires systematic theories and complex technical means to obtain effective support, and has very strict requirements on the growth environment of animals. Zebrafish has the advantages of high genetic homology with humans, short development cycle, and small size, which makes it possible to use it as an animal model for screening active drugs. The current screening method for anti-AD drugs using zebrafish models is mainly based on a large amount of behavioral data and biochemical indicators, such as swimming distance, swimming speed, reaction ability, number of apoptotic cells in the brain, number of pathological plaques formed by Aβ protein aggregation, etc.
[0003] Such as application number 202110295180.0, invention name A method for screening anti-Alzheimer's drugs based on behavioral and biochemical indicators and drugs screened by this method. The invention discloses the use of behavioral and biochemical indicators to screen anti-Alzheimer's drugs to determine whether the drug has anti-Alzheimer's effects. However, during the operation of this method, the following problems were found: First, it is necessary to record the ability of each fish to recover from stress stimulation in an alternating light and dark environment within 60 minutes, and the amount of statistical data is large and the cycle is long; second, it is necessary to test the biochemical indicators of zebrafish. Since the size of zebrafish fry is very small, when conducting statistics such as the number of apoptotic cells in the brain and the number of pathological plaques, the accuracy of the experiment is required to be high, otherwise it will affect the accuracy of the experiment.
[0004] How to simplify the analysis of the behavioral data of the zebrafish model, accurately describe the impact of anti-Alzheimer's drug stimulation on behavior, and develop more efficient and accurate anti-Alzheimer's drug screening methods are issues that urgently need to be addressed. Summary of the invention
[0005] To solve the above problems, the purpose of the present invention is to provide an anti-Alzheimer's disease marker gene and a method and drug for screening anti-Alzheimer's disease drugs based on the gene, that is, the use of the drug soycerebroside II in anti-Alzheimer's disease.
[0006] In order to achieve the above object, the present invention is implemented through the following technical solutions:
[0007] Application of an anti-Alzheimer's disease marker gene in screening anti-Alzheimer's disease drugs, wherein the anti-Alzheimer's disease marker gene is pla2g12a.
[0008] Preferably, a zebrafish larvae Alzheimer's disease model is first constructed, the zebrafish larvae are initially screened through behavioral screening, and then upstream and downstream primers are designed for the anti-Alzheimer's disease marker gene pla2g12a, and RT-qPCR verification is performed to determine whether the drug to be screened has an anti-Alzheimer's disease effect based on the expression trend of the anti-Alzheimer's disease marker gene pla2g12a.
[0009] The present invention also includes a method for screening anti-Alzheimer's disease drugs based on the above anti-Alzheimer's disease marker genes, comprising the following steps:
[0010] (1) Construction of zebrafish larvae Alzheimer's disease model
[0011] Three-day-old zebrafish larvae were used as model animals and induced with 80 μM AlCl3 solution for 3 consecutive days to establish a zebrafish larvae Alzheimer's disease model.
[0012] (2) Determine the maximum safe concentration LC1 of the drug to be screened and the positive drug galantamine for 3-day-old zebrafish fry treated continuously for 3 days from 3 to 6 days of age;
[0013] (3) Treatment of zebrafish fry
[0014] Three-day-old zebrafish fry were randomly divided into a blank control group, an AlCl3 model group, a positive drug group, and a drug screening group. The number of fish in each group was the same. The zebrafish fry were placed in a 24-well cell culture plate, with 10 to 15 fish in each well. In the blank control group, only fresh fish water was added to each well of the cell culture plate. In the AlCl3 model group, 80 μM AlCl3 solution was added to each well of the cell culture plate. In the positive drug group and the drug screening group, 80 μM AlCl3 solution and positive drugs / drugs to be screened with a maximum safe concentration of less than LC1 were added to each well of the cell culture plate. During the experimental treatment of zebrafish fry, water and drug solution were changed once a day. The fry were immersed in drugs for 3 days without feeding.
[0015] (4) Behavioral screening
[0016] Randomly select each group of fry, wash them with fish water, place them in a 48-well plate, add 1 ml of fish water to each well, put them into the dark box of the Zebrabox zebrafish behavior analyzer, and treat the zebrafish fry with a cycle of 5 minutes of darkness and 1 minute of light. Record the movement trajectory of each group of fry, conduct behavioral tests, and intercept the movement distance and speed change data 10 seconds before and after the light-dark alternation point for analysis; conduct three experiments for each group of fry, and calculate the average value;
[0017] (5) Based on real-time PCR technology, the expression level of the anti-Alzheimer's disease marker gene pla2g12a in each group was detected to screen out anti-Alzheimer's disease drugs:
[0018] Primer sequences designed to combat the Alzheimer's disease marker gene pla2g12a:
[0019] pla2g12a-RT-F:TCATCCTCTCCTGCGTTACC,
[0020] pla2g12a-RT-R:GATCAGGTCCAGAGCCATGT,
[0021] The zebrafish from different treatment groups after behavioral recording were collected, washed two to three times with fish water, transferred to centrifuge tubes, and dried the upper liquid after high-speed centrifugation, leaving the zebrafish tissue at the bottom; the total RNA of the zebrafish in different experimental groups was extracted using an RNA extraction kit, and the RNA concentration was determined using an ultra-micro spectrophotometer. The RNA was reversed into cDNA using a reverse transcription kit, and the cDNA after the reverse was completed in each group was used as a template, and the primers to be tested were added to amplify in the qRT-PCR instrument according to the instructions of real-time fluorescence quantitative PCR. Three parallel experiments were set up for each group to detect the expression level of the anti-Alzheimer's disease marker gene pla2g12a in each group;
[0022] (6) Criteria for judging anti-Alzheimer's disease drugs:
[0023] Compared with the AlCl3 model group, the total swimming distance of the anti-Alzheimer's drug group increased and the swimming speed increased; the expression changes of the anti-Alzheimer's marker gene pla2g12a of the anti-Alzheimer's drug group and the positive drugs galantamine and donepezil were the same, all of which were up-regulated.
[0024] Preferably, the drugs to be screened are salvia miltiorrhiza extract, Acorus tatarinowii extract, Eucommia ulmoides male flower extract, Ginkgo biloba leaf extract and soybean cerebroside II.
[0025] The present invention also includes an anti-Alzheimer's disease drug, soybean cerebroside II, which is screened out using the above method.
[0026] Compared with the prior art, the present invention has the following advantages:
[0027] The present invention uses transcriptomics to clarify the anti-Alzheimer's disease marker gene pla2g12a, which is a gene unrelated to the nervous system and is a homologous gene shared by humans and zebrafish. First, a zebrafish larvae Alzheimer's disease model is constructed, and the zebrafish larvae are preliminarily screened by behavioral data of 10 seconds before and after the alternation of light and dark, and then upstream and downstream primers are designed for the anti-Alzheimer's disease marker gene pla2g12a, and RT-qPCR verification is performed. Since the expression trends of the anti-Alzheimer's disease marker gene pla2g12a in the positive drug galantamine group, donepezil group and soybean cerebroside II group are consistent, it is determined that soybean cerebroside II has an anti-Alzheimer's disease effect. The screening method of the anti-Alzheimer's disease drug of the present invention greatly saves the time of drug screening, improves the screening efficiency, and provides a new idea for accurately and efficiently screening anti-Alzheimer's disease drugs. BRIEF DESCRIPTION OF THE DRAWINGS
[0028] Figure 1 Schematic diagram of the total distance traveled by each group of zebrafish within 20 seconds before and after the light-dark transition;
[0029] Figure 2 Schematic diagram of the speed of each group of zebrafish within 20 seconds before and after the light-dark transition;
[0030] Figure 3 for Figure 2 Schematic diagram of the speed of the blank group and the AlCl3 model group within 20 seconds before and after the light-dark alternation;
[0031] Figure 4 for Figure 2 The speed diagram of the galantamine positive drug control group and the soybean cerebroside II drug treatment group within 20 seconds before and after the light-dark alternation;
[0032] Figure 5 for Figure 2 Schematic diagram of the speed of the Salvia miltiorrhiza extract drug-treated group and the Acorus tatarinowii extract drug-treated group within 20 seconds before and after the light-dark alternation;
[0033] Figure 6 for Figure 2 Schematic diagram of the speed of the Eucommia male flower extract drug-treated group and the Ginkgo biloba leaf extract drug-treated group within 20 seconds before and after the light-dark alternation;
[0034] Figure 7 It is a schematic diagram of the expression level results of the zebrafish gene pla2g12a in each group;
[0035] Figure 8 Schematic diagram of the total distance traveled by each group of zebrafish within 20 seconds before and after the light-dark transition;
[0036] Fig. 9 Schematic diagram of the speed of zebrafish in each group during 5 cycles of light-dark alternation;
[0037] Fig.10 for Fig. 9 Schematic diagram of the speed of the blank group and AlCl3 model group in 5 cycles of light-dark alternation;
[0038] Fig.11 for Fig. 9 Schematic diagram of the speed of the galantamine positive drug control group and the soybean cerebroside II drug treatment group in 5 cycles of light-dark alternation;
[0039] Fig.12 for Fig. 9 Schematic diagram of the speed of the Salvia miltiorrhiza extract drug treatment group and the Acorus tatarinowii extract drug treatment group in 5 cycles of light-dark alternation;
[0040] Fig.13 for Fig. 9 Schematic diagram of the speed of the Eucommia male flower extract drug-treated group and the Ginkgo biloba leaf extract drug-treated group during 5 cycles of light-dark alternation.
[0041] Fig.14 Figure 2 shows the accumulation of Aβ plaques in zebrafish. Aβ plaques in the brain tissues of Ctl, AlCl3, and AlCl3+galantamine or AlCl3+daidzein II groups were stained with thioflavin S (Aβ is marked with arrows). Scale bar = 100 μm;
[0042] Fig.15 The gene expression of the marker gene pla2g12a in the mouse AD model group and the two positive drug groups;
[0043] Fig.16 This is a picture showing the AD-like behavior results of zebrafish with pla2g12a gene knockdown;
[0044] Fig.17 To show the accumulation of Aβ plaques in pla2g12a gene knockdown zebrafish, Thioflavin S was used to stain the Aβ plaques in the brain tissues of Ctl, pla2g12a knockdown zebrafish, pla2g12a knockdown zebrafish + galantamine, and pla2g12a knockdown zebrafish + soycerebroside II groups (Aβ is marked with arrows), Scale bar = 100 μm.
[0045] Figure symbols: 1: blank group; 2: AlCl3 model group; 3: galanthamine positive drug control group; 4: salvia miltiorrhiza extract drug treatment group; 5: Acorus tatarinowii extract drug treatment group; 6: soycerebroside II drug treatment group; 7: Eucommia male flower extract drug treatment group; 8: Ginkgo biloba extract drug treatment group; 9: donepezil positive drug control group; 10: marker gene pla2g12a knockout experiment-blank control group; 11: marker gene pla2g12a knockout experiment-AD modeling group; 12: marker gene pla2g12a knockout experiment-positive drug donepezil group; 13: marker gene pla2g12a knockout experiment-positive drug galanthamine treatment group; 16: marker gene pla2g12a knockout experiment-soycerebroside II drug treatment group;
[0046] *** indicates P < 0.001 compared with the blank group, # indicates P < 0.05 compared with the AlCl3 model group, ## indicates P < 0.01 compared with the AlCl3 model group, and ### indicates P < 0.001 compared with the blank group. DETAILED DESCRIPTION
[0047] The purpose of the present invention is to provide an anti-Alzheimer's disease marker gene and a method and drug for screening anti-Alzheimer's disease drugs based on the gene, that is, to screen the application of the drug soycerebroside II in anti-Alzheimer's disease. The present invention is further described below in conjunction with specific embodiments.
[0048] Example 1
[0049] Preparation:
[0050] 1. Collection of fish eggs
[0051] Healthy, sexually mature zebrafish were placed in a spawning tank at a ratio of 1:1 between male and female at around 16:00 on the same day. The baffles were removed at 8:30 the next day. Fertilized eggs were collected 2 hours later, dead embryos were removed, and the eggs were rinsed three times with culture water. The eggs were transferred to culture water containing 2 mg / L methylene blue and placed in a 28°C incubator for incubation and culture. After 4 hours, the embryos were placed under a microscope for observation, and embryos with normal development were selected for incubation and culture until 3 dpf after fertilization. Dead embryos were removed every day during this period.
[0052] 2. Prepare the drugs to be screened
[0053] Prepare Chinese medicinal materials: Salvia miltiorrhiza, Acorus tatarinowii, Eucommia ulmoides male flowers and Ginkgo biloba leaves; purchase soybean cerebroside II, donepezil and galantamine at the same time.
[0054] The above Chinese medicine raw materials are extracted by water extraction to extract the effective ingredients in the Chinese medicine raw materials:
[0055] The above Chinese medicine raw materials are ground into powders respectively, added into a round-bottom flask, 3 to 5 times the weight of water of the Chinese medicine raw material powder is added thereto, distilled and purified for at least 5 hours, cooled and centrifuged, the supernatant is collected, the lower liquid is filtered to obtain a filtrate, the supernatant and the filtrate are rotary evaporated to remove water, and a Chinese medicine extract is obtained;
[0056] The effective substances extracted from salvia miltiorrhiza, calamus tatarinowii, eucommia male flower and ginkgo biloba leaf are salvia miltiorrhiza extract, calamus tatarinowii extract, eucommia male flower extract and ginkgo biloba leaf extract respectively.
[0057] Transcriptomics identifies marker genes for resistance to Alzheimer's disease, including the following steps:
[0058] (1) Construction of zebrafish larvae Alzheimer's disease model (AD modeling)
[0059] Three-day-old zebrafish larvae were used as model animals. Zebrafish larvae at 3 dpf after fertilization were randomly transferred into a six-well plate, with about 40 larvae per well. They were induced with 80 μM AlCl3 solution for 3 consecutive days from 3 dpf to 6 dpf to establish a zebrafish larvae Alzheimer's disease model.
[0060] (2) Determine the maximum safe concentration LC1 of the drug to be screened and the positive drug galantamine for 3-day-old zebrafish fry treated continuously for 3 days from 3 to 6 days of age;
[0061] Three-day-old zebrafish fry were randomly divided into a blank group and several experimental groups (Salvia miltiorrhiza extract, Acorus calamus extract, Eucommia male flower extract, Ginkgo biloba leaf extract, and soybean cerebroside II), with the same number of fish in each group. The zebrafish fry were placed in a 24-well cell culture plate, with 8 to 12 fish per well, preferably 10 fish. The 24-well cell culture plate was immersed in different gradient concentrations of the drug to be screened for 3 days, and each concentration test was repeated 3 times. The mortality rate of the zebrafish was recorded, and the maximum safe concentration of the drug in the experimental group and the control group was calculated and determined by SPSS software.
[0062] The maximum safe concentrations of Salvia miltiorrhiza extract, Acorus calamus extract, Eucommia ulmoides male flower extract, Ginkgo biloba leaf extract, and soybean cerebroside II are shown in Table 1.
[0063] Table 1 Maximum safe concentration of drugs
[0064] Drug Name Maximum safe concentration table Salvia miltiorrhiza extract 554 μg / mL Acorus calamus extract 354 μg / mL Eucommia ulmoides male flower extract 206 μg / mL Ginkgo Biloba Extract 135 μg / mL Soybean Cerebroside II 18 μg / mL
[0065] According to the literature “The development of advanced structural framework as multi-target-directed ligands for the treatment of Alzheimer's disease, Z. Sang, Eur J Med Chem 192 (2020) 112180”, the maximum safe concentration of galantamine is 0.5 mM, and the experimental concentration selected in the present invention is 0.2 mM;
[0066] According to the literature “Zebrafish is a predictive model for identifying compounds that protect against brain toxicity in severe acute organophosphorus intoxication, M. Faria, Arch Toxicol 91(4)(2017)1891-1901”, the maximum safe concentration of donepezil is 8.0 μM, and the experimental concentration selected in the present invention is 6.0 μM.
[0067] 3. Transcriptomics identifies marker genes for resistance to Alzheimer’s disease
[0068] 3dpf zebrafish fry were transferred to a 6-well plate, with 3 wells in each group and 30-40 fish in each well. A blank group, AlCl3 model group, and drug group (galanthamine group and donepezil group) were set up. 5ml of fresh fish water was added to the blank group, and the galanthamine group and donepezil group were co-treated with the corresponding optimal concentration of drug solution and 80μM AlCl3 solution. When the zebrafish were treated until 6dpf, they were washed 2-3 times with fish water and pure water, transferred to 1.5ml centrifuge tubes, and the total RNA of the four groups of zebrafish was extracted respectively;
[0069] The total RNA of the four groups of zebrafish after extraction was subjected to transcriptomics research, and the gene expression differences of the four groups of zebrafish were analyzed for significance. Statistical methods were used to perform information analysis and compare the gene expression differences of the four groups of zebrafish. The specific genes sought by the present invention meet the following requirements: ① The expression of the target gene in the AlCl3 model group and the drug group is opposite, such as the expression of the target gene is down-regulated in the AlCl3 model group, and the expression of the target gene in the two positive drug groups (donepezil group, galantamine group) should be up-regulated; ② The target gene is not related to the nervous system; ③ The target gene is a homologous gene shared by humans and zebrafish. After analyzing the transcriptome sequencing results, pla2g12a is a marker gene that meets the above requirements.
[0070] 4. Drug Screening in the AlCl3 Model Zebrafish
[0071] (1) Treatment of zebrafish larvae
[0072] Three-day-old zebrafish fry were randomly divided into a blank control group, an AlCl3 model group, a positive drug group, and a drug screening group. The number of fish in each group was the same. The zebrafish fry were placed in a 24-well cell culture plate, with 3 wells in each group and 10 to 15 fish in each well. In the blank control group, only fresh fish water was added to each well of the cell culture plate. In the AlCl3 model group, 80 μM AlCl3 solution was added to each well of the cell culture plate. In the positive drug group and the drug screening group, 80 μM AlCl3 solution and positive drugs / drugs to be screened at a concentration below LC1 were added to each well of the cell culture plate (as shown in Table 2). During the experimental treatment of zebrafish fry, water and drug solution were changed once a day. The fry were immersed in drugs for 3 days without feeding during this period.
[0073] The LC1 concentration of positive drugs / drugs to be screened was determined according to the reference “Anti-Inflammation Associated Protective Mechanism of Berberine and its Derivatives on Attenuating Pentylenetetrazole-Induced Seizures in Zebrafish, Baoyue Zhang, Journal of Neuroimmune Pharmacology (2020) 15: 309-325”.
[0074] The drugs in the positive drug group are galantamine and donepezil; the drugs in the drug screening group are salvia miltiorrhiza extract, Acorus tatarinowii extract, Eucommia ulmoides male flower extract, Ginkgo biloba leaf extract and soybean cerebroside II.
[0075] Table 2 Drug selection concentration table
[0076] Drug Name concentration Salvia miltiorrhiza extract 90 μg / mL Acorus calamus extract 50 μg / mL Eucommia ulmoides male flower extract 50 μg / mL Ginkgo Biloba Extract 30 μg / mL Soybean Cerebroside II 1 μg / mL Galantamine 0.2mM Donepezil 6.0μM
[0077] (2) Behavioral screening (donepezil is not screened)
[0078] 24 fry were randomly selected from each group, washed three times with fish water, placed in a 48-well plate, 1 ml of fish water and 1 fry were added to each well, and placed in the dark box of the Zebrabox zebrafish behavior analyzer for 10 minutes. The zebrafish fry were then treated with a cycle of 5 minutes of darkness and 1 minute of light. The movement trajectory of each group of fry was recorded, and behavioral tests were performed. The movement distance and speed change data of 10 seconds before and after a light-dark alternation point were intercepted and analyzed.
[0079] The total distance traveled by each group of zebrafish during the 20-second light-dark alternation (10 seconds before and after) is as follows: Figure 1 As shown. Compared with the blank group, the total distance of zebrafish activity in the AlCl3 model group was significantly reduced (P < 0.001), indicating that the Alzheimer's disease model induced by aluminum chloride was successful. Within the experimental concentration range, the galanthamine positive drug group and soybean cerebroside II group could increase the total distance of zebrafish activity induced by aluminum chloride, and compared with the AlCl3 model group, there was a significant difference.
[0080] The speed changes of zebrafish in each group at the 20-second light-dark alternation point (10 seconds before and after) are as follows Figure 2-Figure 6 As shown, the speed of zebrafish in the 15s and 20sAlCl3 model groups was reduced compared with the blank group (P < 0.001). The present invention believes that these two time periods can be used as the main reference points for screening anti-AD active drugs. The positive drugs galanthamine and soycerebroside II both improved the speed of zebrafish in the above time periods. Compared with the AlCl3 model group, there was a significant difference (P < 0.01). Therefore, the positive drug galanthamine and the drug to be screened soycerebroside II can both improve the speed of zebrafish.
[0081] (3) Based on real-time PCR technology, the expression level of the anti-Alzheimer's disease marker gene pla2g12a in each group was detected to screen out anti-Alzheimer's disease drugs:
[0082] 30-40 zebrafish of different treatment groups were collected, washed two to three times with fish water, transferred to centrifuge tubes, and dried the upper liquid after high-speed centrifugation, leaving the bottom zebrafish tissue; total RNA of different experimental groups of zebrafish was extracted using RNA extraction kit, RNA concentration was determined using ultra-micro spectrophotometer, RNA was reversed into cDNA using reverse transcription kit, and the cDNA after reversed in each group was used as template according to the real-time fluorescence quantitative PCR instruction manual, and the primers to be tested were added to amplify in the qRT-PCR instrument, and three parallel experiments were set up for each group to detect the expression level of anti-Alzheimer's disease marker gene pla2g12a in each group; specifically:
[0083] After the behavioral experiment, the juveniles in the blank control group, AlCl3 model group, soybean cerebroside II group and two positive drug groups were washed three times with fish water and pure water. The zebrafish juveniles were collected in 1.5mL EP tubes, 30 in each tube, and stored in a -80℃ refrigerator. When extracting RNA, 350μL lysis buffer was added to each EP tube, mechanically homogenized in a tissue grinder for 2min, pre-cooled in a high-speed centrifuge, centrifuged at 4℃ for 3min, 11000rpm, and the supernatant was added to the clearing column, centrifuged at 11000rpm for 2min, and the inner tube was removed. An equal volume of 70% ethanol solution was added to the outer tube, quickly mixed and transferred to the adsorption column, centrifuged at 11000rpm for 1min, and the supernatant was discarded. 700μL of deproteinization solution was added, and the tube was allowed to stand at room temperature for 1min. After centrifugation at 11000rpm for 1min, the supernatant was discarded, and 500μL of rinsing solution was added for two rinses. Finally, the adsorption column was placed in an empty centrifuge tube and 40 μL of pure water was added. After standing at room temperature for 5 min, the tube was centrifuged at high speed for 1 min. The concentrations of the extracted RNA in different groups were determined using an ultra-micro spectrophotometer and stored in a -80°C refrigerator.
[0084] RNA was quickly reversed into cDNA using a C1000 Touch gradient PCR instrument. The reverse transcription kit instructions were followed and the concentrations of cDNA in different groups were determined using an ultra-micro spectrophotometer and stored in a -20°C refrigerator.
[0085] The inverted cDNA of each group was used as a template, and an 8-row EP tube with a volume of 100 μL was used for the sample loading experiment. The internal reference gene was rpl13a (this gene was predicted to be a structural component of the ribosome, and its expression in zebrafish tended to be stable. This gene was used as a control gene in this project, and the expression data was normalized to reflect the expression changes of the gene pla2g12a). The sample loading system is shown in Table 3. Each experimental treatment group was set up with 3 replicates, and the entire experiment was carried out on an ice box to ensure that the cDNA and primers would not be degraded. After adding the primers to be tested, the changes in gene expression in each group were detected by real-time quantitative fluorescence detection on a Roche real-time fluorescence quantitative PCR instrument, and the amplification program is shown in Table 4.
[0086] Table 3 Real-time PCR reaction system
[0087]
[0088] Table 4 Real-time PCR program
[0089]
[0090] Primer sequences against the Alzheimer's disease marker gene pla2g12a:
[0091] pla2g12a-RT-F:TCATCCTCTCCTGCGTTACC,
[0092] pla2g12a-RT-R:GATCAGGTCCAGAGCCATGT,
[0093] Primer sequence of the internal reference gene rpl13a:
[0094] rpl13a-RT-F:TCTGGAGGACTGTAAGAGGTATGC,
[0095] rpl13a-RT-R: AGACGCACAATCTTGAGAGCAG,
[0096] Statistical analysis
[0097] Statistical analysis was performed using GraphPad Prism 8.0. Data are presented as mean ± standard error. Single factor analysis of variance was used for significant differences, and P < 0.05 was considered statistically significant.
[0098] The expression changes of anti-Alzheimer's disease marker gene pla2g12a in each group are as follows Figure 7 As shown. It can be seen that during the experimental period, the modeling drug aluminum chloride can significantly downregulate the expression of the pla2g12a gene in zebrafish. Within the corresponding drug concentration range, the positive drugs galantamine, donepezil and soybean cerebroside II can upregulate the expression of the pla2g12a gene compared with the AlCl3 model group, and the data are statistically significant; while the difference between the salvia miltiorrhiza extract treatment group and the AlCl3 model group is very small, the Acorus tatarinowii extract treatment group and the Eucommia ulmoides male flower extract treatment group compared with the AlCl3 model group, both downregulated the expression of the pla2g12a gene, and the ginkgo leaf extract treatment group compared with the AlCl3 model group, although the expression of the pla2g12a gene was upregulated, but it was not statistically significant.
[0099] In summary, compared with the AlCl3 model group, the total swimming distance of the soycerebroside II drug increased and the swimming speed increased; the expression changes of the anti-Alzheimer's disease marker gene pla2g12a were the same as those of the positive drugs galantamine and donepezil, both of which were up-regulated. Therefore, soycerebroside II can be used as an anti-Alzheimer's disease drug.
[0100] In the behavioral screening process of step 4, zebrafish larvae were treated with a cycle of 5 minutes of darkness and 1 minute of light, and the movement trajectory of each group of larvae was recorded. The behavioral test was conducted, and the movement distance and speed change data of 5 light-dark cycles were intercepted and analyzed 10 seconds before and after a light-dark alternation point; the total movement distance of each group of zebrafish in 5 cycles of light-dark alternation was as follows Figure 8As shown. It can be seen that the total distance of zebrafish activity in the AlCl3 model group was significantly reduced compared with the blank group (P < 0.001), indicating that the Alzheimer's disease model induced by aluminum chloride was successful. Within the experimental concentration range, the galantamine positive drug group and soybean cerebroside II can increase the total distance of zebrafish activity induced by aluminum chloride, and compared with the AlCl3 model group, there is a significant difference. And each group of data is Figure 2 The trends are basically the same.
[0101] The speed changes of zebrafish in each group during the five cycles of light-dark alternation are as follows Figure 9-13 As shown, it can be seen that the speed of zebrafish shows cyclic changes with the light-dark alternation cycle, especially the speed changes significantly at the light-dark alternation point. Compared with the blank group, the speed of zebrafish in the AlCl3 model group was reduced. Both the positive drug galanthamine and soybean cerebroside II improved the speed of zebrafish in the above time period. Compared with the AlCl3 model group, there was a significant difference (P < 0.01). Therefore, the positive drug galanthamine and the drug to be screened soybean cerebroside II can improve the speed of zebrafish. The other drug groups cannot improve the movement speed of zebrafish. The present invention uses the total movement distance and speed changes of 20 seconds (10 seconds before and after) at the light-dark alternation point to perform behavioral screening on zebrafish, which can intuitively and accurately describe the effect of the drug on the behavior of zebrafish, which is the same as the behavioral results obtained by selecting 5 light-dark alternation times. Therefore, the behavior of the present invention directly selects data within 20 seconds of the light-dark alternation point for processing, which greatly shortens the recording time, reduces the total workload of screening, and improves the efficiency of drug screening.
[0102] (4) Detection of Aβ plaque deposition
[0103] Zebrafish larvae were fixed in 4% paraformaldehyde solution and subsequently embedded in regular agar blocks. They were then frozen at -20°C until sectioning (7 μm intervals). Tissue sections were then stained with Thioflavin S. Briefly, they were washed several times with 0.01 M phosphate-buffered saline (PBS) at room temperature for 5-10 minutes each wash. Subsequently, they were incubated with 0.3% Thioflavin S (Sigma-Aldrich, Darmstadt, Germany) solution overnight at room temperature in the dark. Finally, they were washed with 0.01 M PBS in the dark for 30 minutes and analyzed using a confocal inverted microscope. The results are shown in Figure 2. Fig.14 shown.
[0104] like Fig.14As shown, it indicates the deposition of Aβ plaques in the brain of AD zebrafish. The number of Aβ plaques deposited in AICI3 model zebrafish increased, that is, AD-like pathological changes occurred. After treatment with positive drugs and soybean cerebroside II, the deposition of Aβ plaques decreased, and the AD-like pathological changes in zebrafish were improved. This experimental data proves the scientificity of AICI3 modeling Alzheimer's disease and preliminarily verifies the effectiveness of soybean cerebroside II in anti-AD.
[0105] (5) Gene knockout
[0106] Establishment of mouse model
[0107] The experiment selected the same batch of adult male wild C57 mice and randomly divided them into 5 groups, including normal control group, model control group, and positive drug (donepezil + galantamine) group, with 10 mice in each group. Except for the normal control group, the other groups were injected with β-amyloid protein into the ventricle to induce AD. After the model was successfully established, the positive drug administration group was injected with donepezil and galantamine respectively. Chloral hydrate (400 mg / kg) was first injected intraperitoneally to anesthetize the rats, and routine skin preparation and disinfection were performed. Then, the skin in the middle of the top of the rat's skull was cut open and the rat was fixed with a brain stereotaxic instrument. The positioning method was: take a flat skull position, determine the right 3.8mm, 2.5mm beside the midline, and 3.0mm below the skull surface as the dorsal part of the right hippocampus. Finally, the cerebrospinal fluid was withdrawn, and 1μL Aβ25-35 was slowly injected within 5min with a 10μL microsyringe, and the needle was retained for 10min. The modeling method was based on the literature Luo Lan, Wu Xiaochuan, Gao Huijing, et al. Study on the protective effect of total glycosides of Cistanche deserticola on Alzheimer's disease model rats [J]. Chinese Pharmacy, 2013, 24(23): 2122-5.
[0108] In the early developmental stage of zebrafish embryos, oligonucleotides are directly injected into the cytoplasm of fertilized eggs by microinjection so that they are expressed during embryonic development. After oligonucleotide injection, it is necessary to detect whether the expression level of the target gene is reduced. This is done by real-time quantitative PCR. Ultimately, the phenotypic changes of zebrafish can be observed and recorded, and the effects of target gene knockdown on its development, behavior or other biological characteristics can be analyzed.
[0109] The results are as follows Figure 15-17 shown.
[0110] like Fig.15 As shown in the figure, compared with the blank control group, the gene pla2g12a was significantly decreased in the mouse AD model group; compared with the AD model group, the gene expression in the two positive drug groups was significantly upregulated. This shows that the gene expression pattern is consistent in both the zebrafish AD model and the mouse AD model, which can reflect the clear correlation between the Alzheimer's disease marker gene pla2g12a and AD.
[0111] like Fig.16 As shown, Fig.16 -Figure A shows that the zebrafish pla2g12a gene was successfully knocked down. Fig.16 - In Figure B, the swimming distance of zebrafish with pla2g12a gene knockdown is reduced, while positive drugs and soybean cerebroside II can increase the swimming distance of zebrafish with pla2g12a gene knockdown; Fig.16 -CE graph, the swimming speed of the pla2g12a gene knockdown zebrafish group slowed down, and soycerebroside II and galantamine could improve the slowing down of the pla2g12a gene knockdown zebrafish, showing a significant difference (P < 0.001). Figure 1-2 The above consistency can indicate that the experiment has good repeatability.
[0112] like Fig.17 As shown, it indicates the deposition of Aβ plaques in the brain of AD zebrafish. The number of Aβ plaques deposited in zebrafish with pla2g12a gene knockdown increased, that is, AD-like pathological changes occurred. After treatment with positive drugs and soybean cerebroside II, Aβ plaque deposition decreased, and the AD-like pathological changes in zebrafish were improved. This experimental data further proves the correlation between pla2g12a gene changes and AD symptoms, and further proves the effectiveness of using pla2g12a gene changes to screen anti-AD drugs. This experimental data further proves the correlation between pla2g12a gene changes and AD symptoms, and further proves the effectiveness of using pla2g12a gene changes to screen anti-AD drugs.
[0113] The above data were statistically analyzed using GraphPad Prism 9.5. The data are presented as mean ± standard error (mean ± SEM). One-way analysis of variance was used for significant difference analysis, and P < 0.05 was considered statistically significant.
Claims
1. Application of anti-Alzheimer's disease marker genes in screening anti-Alzheimer's disease drugs, characterized in that: The anti-Alzheimer's disease marker gene is pla2g12a.
2. The use of the anti-Alzheimer's disease marker gene in screening anti-Alzheimer's disease drugs according to claim 1, characterized in that: First, a zebrafish larvae Alzheimer's disease model was constructed, and the zebrafish larvae were initially screened through behavioral analysis. Then, upstream and downstream primers were designed for the anti-Alzheimer's disease marker gene pla2g12a, and RT-qPCR verification was performed. Based on the expression trend of the anti-Alzheimer's disease marker gene pla2g12a, it was determined whether the drug to be screened had an anti-Alzheimer's disease effect.
3. A method for screening anti-Alzheimer's disease drugs based on the anti-Alzheimer's disease marker gene according to claim 1, characterized in that: The following steps are involved: (1) Construction of zebrafish larvae Alzheimer's disease model Three-day-old zebrafish larvae were used as model animals and induced with 80 μM AlCl3 solution for 3 consecutive days to establish a zebrafish larvae Alzheimer's disease model. (2) Determine the maximum safe concentration LC1 of the drug to be screened and the positive drug galantamine for 3-day-old zebrafish fry treated continuously for 3 days from 3 to 6 days of age; (3) Treatment of zebrafish fry Three-day-old zebrafish fry were randomly divided into a blank control group, an AlCl3 model group, a positive drug group, and a drug screening group. The number of fish in each group was the same. The zebrafish fry were placed in a 24-well cell culture plate, with 10 to 15 fish in each well. In the blank control group, only fresh fish water was added to each well of the cell culture plate. In the AlCl3 model group, 80 μM AlCl3 solution was added to each well of the cell culture plate. In the positive drug group and the drug screening group, 80 μM AlCl3 solution and positive drugs / drugs to be screened with a maximum safe concentration of less than LC1 were added to each well of the cell culture plate. During the experimental treatment of zebrafish fry, water and drug solution were changed once a day. The fry were immersed in drugs for 3 days without feeding. (4) Behavioral screening Randomly select each group of fry, wash them with fish water, place them in a 48-well plate, add 1 ml of fish water to each well, put them into the dark box of the Zebrabox zebrafish behavior analyzer, and treat the zebrafish fry with a cycle of 5 minutes of darkness and 1 minute of light. Record the movement trajectory of each group of fry, conduct behavioral tests, and intercept the movement distance and speed change data 10 seconds before and after the light-dark alternation point for analysis; conduct three experiments for each group of fry, and calculate the average value; (5) Based on real-time PCR technology, the expression level of the anti-Alzheimer's disease marker gene pla2g12a in each group was detected to screen out anti-Alzheimer's disease drugs: Primer sequences designed to combat the Alzheimer's disease marker gene pla2g12a: pla2g12a-RT-F:TCATCCTCTCCTGCGTTACC, pla2g12a-RT-R:GATCAGGTCCAGAGCCATGT, The zebrafish from different treatment groups after behavioral recording were collected, washed two to three times with fish water, transferred to centrifuge tubes, and dried the upper liquid after high-speed centrifugation, leaving the zebrafish tissue at the bottom; the total RNA of the zebrafish in different experimental groups was extracted using an RNA extraction kit, and the RNA concentration was determined using an ultra-micro spectrophotometer. The RNA was reversed into cDNA using a reverse transcription kit, and the cDNA after the reverse was completed in each group was used as a template, and the primers to be tested were added to amplify in the qRT-PCR instrument according to the instructions of real-time fluorescence quantitative PCR. Three parallel experiments were set up for each group to detect the expression level of the anti-Alzheimer's disease marker gene pla2g12a in each group; (6) Criteria for judging anti-Alzheimer's disease drugs: Compared with the AlCl3 model group, the total swimming distance of the anti-Alzheimer's drug group increased and the swimming speed increased; the expression changes of the anti-Alzheimer's marker gene pla2g12a of the anti-Alzheimer's drug group and the positive drugs galantamine and donepezil were the same, all of which were up-regulated.
4. The method for screening anti-Alzheimer's disease drugs based on anti-Alzheimer's disease marker genes according to claim 3, characterized in that: The drugs to be screened are salvia miltiorrhiza extract, Acorus tatarinowii extract, Eucommia ulmoides male flower extract, Ginkgo biloba leaf extract and soybean cerebroside II.
5. An anti-Alzheimer's drug screened by the method of claim 3, characterized in that: The anti-Alzheimer's disease drug is soybean cerebroside II.
Citation Information
Patent Citations
Cordyceps sinensis extract as well as preparation method and application thereof
CN115028671A
Method for screening medicine for refreshing and restoring consciousness and application of asperuloside in refreshing and restoring consciousness
CN115247211A
A combination of an NMDA-antagonist and acetylcholine esterase inhibitors for the treatment of alzheimer's disease
SG107527A1
Method and composition for treating alzheimers
US20230165884A1
